Nearly three million American women have been diagnosed with the most common vaginal condition of midlife. More than seven in ten of them walked out with no treatment at all [4].
That figure comes from a 2025 analysis of real medical records, not a small study or a single clinic [4]. It is the clearest snapshot we have of a quiet failure: the symptom gets named, and then nothing happens.
It is tempting to read that as women not speaking up for themselves. The evidence points somewhere else entirely.
The silence starts long before the appointment
Begin with how few women even have the language for what they feel. In an international survey of 3,520 postmenopausal women, 45 percent reported vaginal symptoms, yet only 4 percent connected those symptoms to a real, nameable condition [1].
Most assumed it was simply aging, and something to live with. Nearly two thirds did not realize the changes were chronic and treatable, and 44 percent did not have a gynecologist to ask in the first place [1].
When the symptom has no name and there is no one to bring it to, silence is not really a choice. It is the only available outcome.
You cannot raise a problem you have been taught to expect and accept. That survey was industry-sponsored, as many menopause surveys are, but its size makes the pattern hard to wave away.
"It's normal, just cope" is the message women absorb
When researchers asked women in the US directly, the picture sharpened. Most believed vaginal symptoms were a normal part of getting older and something to endure rather than treat [2].
They were also hesitant to bring it up, and not because they did not want help. They were waiting for someone in a white coat to raise it first [2].
Here is the part that reframes everything. Those same women said they wanted accurate information from their providers and were ready to act on it, if only the clinician would open the door [2]. The willingness was there. The invitation was not.
A system problem wearing a personal costume
It is easy to file all of this under individual shyness. But notice where the conversation keeps stalling, and it is rarely inside the woman's head.
A typical primary care visit is short, and an intimate symptom is the easiest item to push to the end of a list that never quite gets there. Family and friends tend to pass along the same advice they once received, which is to wait it out. Each person quietly assumes it is someone else's job to bring it up.
So women improvise. When no real door opens, the search bar and anonymous forums become the default clinic, which is how a stranger's comment thread ends up standing in for a specialist. None of that is a character flaw. It is what people do when the official channels are too rushed, too awkward, or too far away to use.
Read that again. When 34 percent of women with these symptoms never seek any professional help at all [5], that is not three in ten being timid. That is a referral pathway with no on-ramp.
Failure one: medicine treats it as minor
The vaginal health conversation has been squeezed between two failures, and the first is clinical.
Even with a diagnosis on the chart, treatment often does not follow. That 71 percent untreated rate was not caused by a shortage of options, because safe and effective therapies exist [4]. It reflects a condition the system has quietly ranked as low priority, year after year. The records stretched across two decades, and the pattern barely shifted [4].
Awareness campaigns have barely moved the needle. A review comparing repeated surveys found only minimal gains in women's understanding over the years, despite all the marketing and education aimed at them [2].
Failure two: wellness treats it as a vibe
The second failure arrives from the opposite direction.
As clinics underplayed these symptoms, the wellness aisle rushed in with products framed as self-care rather than science. The catch is that over-the-counter options vary enormously in quality, and some can irritate the very tissue they promise to comfort [3].
That leaves women with two thin choices. One side signals that it barely matters. The other signals that it is easily fixed with the right purchase. Neither offers the option in the middle, which is real information delivered by people who take the subject seriously.
What the silence actually costs
This is not a small inconvenience that resolves on its own. Vaginal dryness affects more than half of postmenopausal women, and it stays under-reported and under-treated precisely because the path to help is blocked [3].
Left unaddressed, these changes can shape comfort, intimacy, and daily quality of life, often for years [3]. The cost is not only physical. It is the slow lesson that this part of your health does not count.
And it is avoidable. The same research that documents the silence also shows women are not refusing information. They are starved of it, and they move quickly once it is finally offered [2].
The missing piece was never courage. It is a place where the science is explained plainly, the symptoms are treated as legitimate, and the ingredient on the label actually means something.
That lens is worth bringing to any product, too. Hyaluronic acid holds water against tissue, and lactic acid supports a healthy vaginal pH, and those mechanisms are knowable rather than mysterious. It is the standard we built Neycher around: formulas chosen for what the research supports, not for what is easy to sell. A label you can actually understand is part of the answer, not a marketing afterthought.
How the silence actually breaks
The fix is not louder self-advocacy demanded from women who are already carrying enough.
It is naming the symptom out loud at the next visit, even if you have to be the one to start, since the research shows many providers are waiting for exactly that cue [2]. It is treating vaginal changes as a genuine health topic rather than a personal flaw or a passing mood.
The silence was never about shame. It is what happens when capable people adapt to systems that do not listen. Give the conversation a real home, and the adapting can finally stop.
Sources
[1] Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey. Climacteric. 2012;15(1):36-44. doi:10.3109/13697137.2011.647840. PMID: 22168244. https://pubmed.ncbi.nlm.nih.gov/22168244/
[2] Krychman M, Graham S, Bernick B, Mirkin S, Kingsberg SA. The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate. J Sex Med. 2017;14(3):425-433. doi:10.1016/j.jsxm.2017.01.011. PMID: 28202319. https://pubmed.ncbi.nlm.nih.gov/28202319/
[3] Potter N, Panay N. Vaginal lubricants and moisturizers: a review into use, efficacy, and safety. Climacteric. 2021;24(1):19-24. doi:10.1080/13697137.2020.1820478. PMID: 32990054. https://pubmed.ncbi.nlm.nih.gov/32990054/
[4] Ghosh A, D'Amico MJ, Shah YB, Smith WR, Shah MS, Lallas CD, Murphy AM. Treatment patterns for genitourinary syndrome of menopause: a TriNetX analysis. Can J Urol. 2025;32(6):627-632. doi:10.32604/cju.2025.067575. PMID: 41496540. https://pubmed.ncbi.nlm.nih.gov/41496540/
[5] Frank SM, Ziegler C, Kokot-Kierepa M, Maamari R, Nappi RE. Vaginal Health: Insights, Views & Attitudes (VIVA) survey - Canadian cohort. Menopause Int. 2013;19(1):20-27. doi:10.1258/mi.2012.012034. PMID: 23201626. https://pubmed.ncbi.nlm.nih.gov/23201626/
